Nektar Reorganizes To Position Pegylated, Pulmonary Units For Future Development

Spending cuts amounting to $65 million annually are not driven by lackluster performance of Exubera, CEO Robin maintains.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet